{
    "clinical_study": {
        "@rank": "8413", 
        "arm_group": [
            {
                "arm_group_label": "Arm A", 
                "arm_group_type": "Experimental", 
                "description": "cilinidpine 10mg + valsartan 160mg"
            }, 
            {
                "arm_group_label": "Arm B", 
                "arm_group_type": "Experimental", 
                "description": "cilnidipine 5mg + valsartan 160mg"
            }, 
            {
                "arm_group_label": "Arm C", 
                "arm_group_type": "Active Comparator", 
                "description": "valsartan 160mg"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate of efficacy and safety of cilinidipine plus\n      valsartan and valsartan alone in patients with essential hypertension inadequately\n      controlled on valsartan monotherapy"
        }, 
        "brief_title": "Efficacy/Safety of Cilnidipine Plus Valsartan Versus Valsartan in Patients With Hypertension", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  essential hypertension patients whose blood pressure is not controlled before the\n             study (sDBP\u226590mmHg for drug-treated patients, sDBP\u226595mmHg for drug-naive patients)\n\n        Exclusion Criteria:\n\n          -  sSBP\u226580mmHg after 4weeks of valsartan 160mg treatment\n\n          -  has a history of hypersensitivity to dihydropyridines or angiotensin II receptor\n             blockers"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "279", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02145104", 
            "org_study_id": "ID_IDCV_1302"
        }, 
        "intervention": {
            "arm_group_label": [
                "Arm A", 
                "Arm B", 
                "Arm C"
            ], 
            "intervention_name": "valsartan 160mg, cilnidipine 10mg, cilinidipine 5mg", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Cilnidipine", 
                "Valsartan"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 20, 2014", 
        "location": {
            "contact": {
                "last_name": "Dong Ju Choi, PhD, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Seong Nam", 
                    "country": "Korea, Republic of", 
                    "state": "Kyung-gi"
                }, 
                "name": "Seoul National University Bundang Hospital"
            }, 
            "investigator": {
                "last_name": "Dong Ju Choi, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "3", 
        "official_title": "Comparison of the Efficacy and Safety of Cilnidipine 10mg/Valsartan 160mg Combination Therapy, Cilnidipine 5mg/Valsartan 160mg Combination Therapy and Valsartan 160mg Monotherapy in Hypertensive Patients Inadequately Controlled With Valsartan 160mg Monotherapy: a Multicenter, Randomized, Double Blind Phase III Study", 
        "overall_contact": {
            "email": "yapark@ildong.com", 
            "last_name": "Yoan park, Master", 
            "phone": "82-2-526-3524"
        }, 
        "overall_official": {
            "affiliation": "Seoul National University Bundang Hospital", 
            "last_name": "Dong Ju Choi, M.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: MFDS", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "change from baseline in mean sDBP", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02145104"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "change from baseline in mean sDBP", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "measure": "change from baseline in mean sSBP", 
                "safety_issue": "No", 
                "time_frame": "4, 8 weeks"
            }
        ], 
        "source": "IlDong Pharmaceutical Co Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "IlDong Pharmaceutical Co Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}